Details of the Drug

General Information of Drug (ID: DMOU1PK)

Drug Name

Praziquantel

Synonyms

Azinox; Biliricide; Biltricide; Cesol; Cisticid; Cutter; Cysticide; Droncit; Drontsit; Prasiquantel; Praziquantelum; Pyquiton; Traziquantel; Bayer Brand of Praziquantel; Cutter Tape Tabs; Merck Brand of Praziquantel; Embay 8440; P 4668; Bay-8440; Biltricide (TN); EMBAY-8440; NPFAPI-02; Praziquantelum [INN-Latin]; Biltricide, Droncit, Praziquantel; Praziquantel (JAN/USP/INN); Praziquantel [USAN:INN:BAN:JAN]; Praziquantel, (R)-Isomer; Praziquantel, (S)-Isomer; Praziquantel, (+-)-Isomer; (+-)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; (11bS)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a) isoquinolin-4-one; 8440, EMBAY

Indication

Disease Entry	ICD 11	Status	REF
Flatworm infection	1F70-1F86	Approved	[1]

Therapeutic Class

Anthelmintics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

312.4

Topological Polar Surface Area (xlogp)

2.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is rapidly absorbed [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination: 2% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 0.8 - 1.5 hours (in serum) [4]
Metabolism: The drug is metabolized via renal [2]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 240.07001 micromolar/kg/day [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.4 mg/mL [3]

Chemical Identifiers

Formula: C19H24N2O2
IUPAC Name: 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one
Canonical SMILES: C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2
InChI: InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2
InChIKey: FSVJFNAIGNNGKK-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4891
ChEBI ID: CHEBI:91583
CAS Number: 55268-74-1
DrugBank ID: DB01058
TTD ID: D0L9ZR
INTEDE ID: DR1329
ACDINA ID: D00549

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutathione-dependent PGD synthase (HPGDS)	TTCYE56	HPGDS_HUMAN	Inhibitor	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[8]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[8]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[9]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[9]
Cytochrome P450 3A43 (CYP3A43)	DEO1IE3	CP343_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Flatworm infection

ICD Disease Classification

1F70-1F86

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glutathione-dependent PGD synthase (HPGDS)	DTT	HPGDS	1.63E-05	0.34	0.71
Cytochrome P450 3A43 (CYP3A43)	DME	CYP3A43	1.55E-01	-2.09E-02	-1.34E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.36E-01	1.62E-02	1.08E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.96E-01	-3.17E-03	-1.84E-02
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	2.40E-01	-3.31E-02	-1.97E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Praziquantel (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Praziquantel caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[60]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Praziquantel caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[60]
Arn-509	DMT81LZ	Major	Increased metabolism of Praziquantel caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[60]
Oritavancin	DM28D05	Moderate	Increased metabolism of Praziquantel caused by Oritavancin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[60]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Praziquantel caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[60]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Praziquantel caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[61]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Praziquantel caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[62]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Praziquantel caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[63]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Praziquantel caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[60]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Praziquantel caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[60]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Praziquantel caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[60]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Praziquantel caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[60]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Praziquantel caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[60]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Praziquantel caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[60]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Praziquantel caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[64]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Praziquantel caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[60]
Rifapentine	DMCHV4I	Major	Increased metabolism of Praziquantel caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[60]
MK-1439	DM215WE	Moderate	Increased metabolism of Praziquantel caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Praziquantel caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Praziquantel caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Praziquantel caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[60]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Praziquantel caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[60]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Praziquantel caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[60]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Praziquantel caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[60]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Praziquantel caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[60]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Praziquantel caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[66]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Praziquantel caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[67]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Praziquantel caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[68]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Praziquantel caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[60]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Praziquantel caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[60]
Exjade	DMHPRWG	Moderate	Increased metabolism of Praziquantel caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[60]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Praziquantel caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[66]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Praziquantel caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[69]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Praziquantel caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[70]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Praziquantel caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[71]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Praziquantel caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[72]
Enzalutamide	DMGL19D	Major	Increased metabolism of Praziquantel caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[60]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Praziquantel caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[60]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Praziquantel caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[60]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Praziquantel caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[62]
Armodafinil	DMGB035	Moderate	Increased metabolism of Praziquantel caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[60]
LEE011	DMMX75K	Moderate	Decreased metabolism of Praziquantel caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[73]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Praziquantel caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[60]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Praziquantel caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[74]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Praziquantel caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[60]
-----------


⏷ Show the Full List of 45 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Praziquantel 600 mg tablet	600 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
2	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	X-ray structure of glutathione S-transferase from Schistosoma japonicum in a new crystal form reveals flexibility of the substrate-binding site. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Mar 1;61(Pt 3):263-5.
7	Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4). Acta Pol Pharm. 2006 Sep-Oct;63(5):381-5.
8	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
9	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
10	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
20	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
21	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
22	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
23	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
24	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
25	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
26	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
27	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
28	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
29	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
30	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
31	Drug Interactions Flockhart Table
32	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
33	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
34	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
35	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
36	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
37	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
38	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
39	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
40	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
41	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
42	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
43	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
44	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
45	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
46	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
47	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
48	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
49	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
50	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
51	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
52	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
53	cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001 Feb;59(2):386-92.
54	US patent application no. 2009,0062,529, Multi-cyclic compounds.
55	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
56	Inhibition of glutathione-S-transferase from Plasmodium yoelii by protoporphyrin IX, cibacron blue and menadione: implications and therapeutic bene... Parasitol Res. 2008 Mar;102(4):805-7.
57	A novel method for screening the glutathione transferase inhibitors. BMC Biochem. 2009 Mar 16;10:6.
58	Purification and catalytic properties of glutathione transferase from the hepatopancreas of crayfish macrobrachium vollenhovenii (herklots). J Biochem Mol Toxicol. 2004;18(6):332-44.
59	Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem. 2006 Jun 2;281(22):15277-86.
60	Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
61	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
62	Cerner Multum, Inc. "Australian Product Information.".
63	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
64	Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
65	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
66	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
67	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
68	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
69	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
70	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
71	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
72	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
73	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
74	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.